Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.51 |
| ▸ | SORD | Q00796 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL756721 | 0.85 | CA12 (0.72) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL30801089 | 0.85 | CA12 (0.72) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL2991679 | 0.84 | CA9 (0.51) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL27792831 | 0.83 | CYP11B1 (0.54) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL9008946 | 0.81 | ALOX5 (0.55) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL9008978 | 0.79 | ALOX5 (0.61) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL13290355 | 0.78 | CA12 (0.49) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL758311 | 0.78 | CYP19A1 (0.55) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL761455 | 0.78 | NPC1 (0.55) | CA9CA12AKR1B1MAOBALDH2 | |
| SCHEMBL4709189 | 0.76 | MCL1 (0.57) | CA9CA12AKR1B1MAOBALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| CN-1802372-B | 7-[(1,3-thiazol-2-yl)thio]-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD | 2010-05-12 | — | — | CN | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| CN-1802372-A | 7-[(1,3-thiazol-2-yl)thio]-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD (CA) | 2006-07-12 | — | — | CN | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | CA9 3097/4885CA12 4446/4885AKR1B1 244/4885 |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | CA9 2746/4885CA12 3849/4885AKR1B1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.